The landscape is constantly evolving for imaging technology and biomarkers, and how they impact cancer detection and treatment. Frost & Sullivan has provided AABME with market intelligence on key innovations for imaging and biomarker technology for oncology.
In the era of personalized medicine, the microbiome industry’s growth trajectory parallels that of genomics in the early 2000s. According to Frost & Sullivan, the global demand for more effective medicines and healthier nutrition will continue to drive the development of microbiomic products. Here are the latest trends.
AABME is a new site offering a range of professional and networking resources to bridge the gap between basic research and applied research. Join the alliance to connect with other practitioners and gain access to premium content – at no cost.